For example, genetic mutations in key regulators of autophagy such as ATG5 or BECN1 and alterations in the expression of components of the ferroptosis pathway like GPX4 and SLC7A11 can affect the susceptibility of HCC cells to therapies that target these pathways. This evidence concerns the gene GPX4 and hepatocellular carcinoma.